
Cardiovascular disease, including heart disease and stroke, is the leading cause of death globally

LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke

The delay was caused by recruitment issues during the COVID-19 pandemic

Potential first-in-class treatment moves closer to EU approval

Swiss pharma also officially opens new London headquarters

Collaboration will see drug offered to patients across the UK via clinical study

If approved could become blockbuster cholesterol treatment

MedCo's cholesterol lowering inclisiran main attraction in planned acquisition

Buyers interested in company as it prepares to file CV drug inclisiran

Less frequent dosing schedules could prove an advantage over rivals

Shares up 14% following announcement